Castle Biosciences (NASDAQ:CSTL) Insider Sells $85,294.30 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 2,678 shares of the stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $31.85, for a total value of $85,294.30. Following the completion of the sale, the insider directly owned 53,615 shares of the company’s stock, valued at $1,707,637.75. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Castle Biosciences Stock Performance

Shares of Castle Biosciences stock opened at $33.04 on Friday. The stock has a market capitalization of $964.44 million, a price-to-earnings ratio of -73.42 and a beta of 1.12. The firm’s fifty day simple moving average is $24.06 and its 200-day simple moving average is $20.43. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.69. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $34.64.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The company had revenue of $83.04 million for the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

CSTL has been the subject of several analyst reports. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 10th. Robert W. Baird boosted their target price on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a report on Tuesday, November 4th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $37.00 price target on shares of Castle Biosciences in a report on Tuesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday, October 30th. Finally, Zacks Research upgraded shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.43.

Institutional Trading of Castle Biosciences

A number of institutional investors have recently modified their holdings of the business. Farther Finance Advisors LLC raised its position in Castle Biosciences by 139,100.0% in the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after acquiring an additional 1,391 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Castle Biosciences during the 3rd quarter worth $35,000. CWM LLC increased its holdings in shares of Castle Biosciences by 80.6% in the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after purchasing an additional 853 shares in the last quarter. Harbour Investments Inc. acquired a new stake in shares of Castle Biosciences in the first quarter valued at about $50,000. Finally, Jones Financial Companies Lllp lifted its stake in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.